Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07091084

A Study of Herbal Supplements in Cancer Survivors With Constipation

The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the effect MZRW has on the gut microbiome. The gut microbiome is a diverse community of microorganisms living in the digestive system, essential for digestion and immune function.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or greater;
  • A diagnosis of cancer with no restrictions placed on type of cancer or stage;
  • Completed surgery, chemotherapy, immunotherapy, and/or radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;
  • Karnofsky functional score of ≥ 60;
  • Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:
  • Straining more than 25% of defecations.
  • Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.
  • Sensation of incomplete evacuation more than one-fourth (25%) of defecations.
  • Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations.
  • Manual maneuvers to facilitate more than one-fourth (25%) of defecations.
  • Fewer than three spontaneous bowel movements per week.
  • Loose stools are rarely present without the use of laxatives.
  • Insufficient criteria for irritable bowel syndrome.
  • Patient should be able to understand and complete all study assessments on their own
  • Patient should be able to understand and provide signed informed consent in English.

Table 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria*

  • Must include two or more of the following:**
  • Straining during more than ¼ (25%) of defecations
  • Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations
  • Sensation of incomplete evacuation more than ¼ (25%) of defecations
  • Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations
  • Fewer than three SBM per week
  • Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)
  • Loose stools are rarely present without the use of laxatives 9. Insufficient criteria for irritable bowel syndrome Note *Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Exclusion criteria

  • Patients who have allergic history to herbs or Chinese medicine;
  • Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL/min/1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);
  • Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;
  • Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;
  • Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.

Treatment and study plan

MZRW

Dietary Supplement

MZRW herbal formula consists of a 7:1 extract of Huo Ma Ren [Hemp Seed 33.4%]; Da Huang (Sheng) [Rhubarb (Fresh) 22.2%]; Bai Shao [Peony (White) 11.1%]; Zhi Shi [Aurantium Immaturus 11.1%]; Hou Po [Magnolia Bark 11.1%]; and Xing Ren [Apricot Kernel 11.1%] - Taken for 2 weeks intervention and 2 weeks follow-up

Other names: Ma-Zi-Ren-Wan

Primary outcomes

  1. Difference of spontaneous bowel movements (SBMs) from baseline to week 2

    Time frame: 2 weeks

    To evaluate the efficacy of a 2-week regimen of oral MZRW vs. placebo on spontaneous bowel movements (SBMs), in terms of SBM therapeutic response (primary efficacy endpoint), among cancer survivors with chronic constipation. SBM response is defined at week 2 as having an increase of ≥ 1 SBM/week from baseline.

Study contacts

Contact information is provided by the study sponsor or research team.

Jun Mao, MD, MSCE

CONTACT

[email protected]

646-608-8552

Yen Nien (Jason) Hou, PharmD

CONTACT

[email protected]

646-608-8555

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Official study title

Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jul 29, 2025
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.